Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction

Summary

This is a phase 1, 2-part, pharmacokinetic study in patients with advanced solid tumors or hematologic malignancies and varying degrees of liver dysfunction (normal function, moderate hepatic impairement or severe hepatic impairment) as defined by the National Cancer Institute (NCI) Organ Dysfunction Working Group.

Timeline

Start

2013-08

Primary completion

2015-03

Completion

2015-03

Drugs

Indications